words lines 0 60 0 20 top 50% bottom top 1 0 0 .22 back 1 0 .001 1 .1 1.5 none top bottom center center true 1 none top top center top true 0 200 .001 none
top bottom top center true 1 none top bottom bottom bottom true 1 none

Oncology

We are proud to be making a profound difference in the lives of people with cancer, by proving oncology treatments on the WHO Essential Medicines List.

Juniper Biologics Healthcare Therapy Oncology Rare Orphan Diseases Gene Therapy Care Onology Man

LEGADA®

LEDAGA® (chlormethine) gel is an alkylating drug indicated for the topical treatment of MF-CTCL in adult patients. LEDAGA® is a gel which is applied topically once a day. The drug has been approved by the European Commission (for the treatment of MF-CTCL in adult patients). Since June 2019, LEDAGA® is commercialized in more than 30 countries including Europe, Canada, Latin America.*

Juniper Biologics Healthcare Therapy Oncology Rare Orphan Diseases Gene Therapy Care Old Man 1600

TRUSELTIQ®

TRUSELTIQ® (infigratinib) capsules 25mg/100mg is indicated for the treatment of adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. TRUSELTIQ® is a pipeline therapy which has already been approved for 2nd Line with Phase 3 Trials and is currently under investigation as a potential first-line treatment for individuals with Adjuvant Urothelial Cancer in Australia.*

*The exact therapeutic indication and registration status may be different in each country. Please consult the official approved product information in your country.